1001401-60-0

Basic information

• Product Name: 1H-1,4-Diazepine-1-carboxylic acid, hexahydro-5-Methyl-, phenylMethyl ester, (5R)-
• Synonyms: 1H-1,4-Diazepine-1-carboxylic acid, hexahydro-5-Methyl-, phenylMethyl ester, (5R)-;Suvorexant InterMediate;(5R)-1H-1,4-Diazepine-1-carboxylic acid, hexahydro-5-Methyl-,phenylMethyl ester;(R)-Benzyl 5-methyl-1,4-diazepane-1-carboxylate/Suvorexant intermediate;New Intermediates;(5R)-Hexahydro-5-methyl-1H-1,4-diazepine-1-carboxylic acid phenylmethyl ester;Benzyl (5R)-5-methyl-1,4-diazepane-1-carboxylate;Benzyl(R)-5-methyl-1,4-diazepane-1-carboxylate
• CAS NO: 1001401-60-0
• Molecular Formula: C₁₄H₂₀N₂O₂
• Molecular Weight: 248.3208
• Mol File: 1001401-60-0.mol

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• CAS DataBase Reference: 1H-1,4-Diazepine-1-carboxylic acid, hexahydro-5-Methyl-, phenylMethyl ester, (5R)-(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-1,4-Diazepine-1-carboxylic acid, hexahydro-5-Methyl-, phenylMethyl ester, (5R)-(1001401-60-0)
• EPA Substance Registry System: 1H-1,4-Diazepine-1-carboxylic acid, hexahydro-5-Methyl-, phenylMethyl ester, (5R)-(1001401-60-0)

Safety Data

• Hazardous Substances Data: 1001401-60-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1H-1,4-Diazepine-1-carboxylic acid, hexahydro-5-Methyl-, phenylMethyl ester, (5R)is used as a pharmaceutical compound for its potential therapeutic applications. Its complex carbon-nitrogen ring structure and various functional groups may contribute to its interaction with biological targets, making it a candidate for the development of new drugs.
Used in Chemical Research:
1H-1,4-Diazepine-1-carboxylic acid, hexahydro-5-Methyl-, phenylMethyl ester, (5R)is used as a research chemical for studying the properties and behavior of diazepines and their derivatives. Its unique structure and enantiomerism provide opportunities for investigating the effects of stereochemistry on chemical reactivity and biological activity.
Used in Drug Synthesis:
1H-1,4-Diazepine-1-carboxylic acid, hexahydro-5-Methyl-, phenylMethyl ester, (5R)is used as an intermediate in the synthesis of other pharmaceutical compounds. Its versatile structure allows for further chemical modifications, making it a valuable building block in the development of new drugs with improved efficacy and reduced side effects.

Upstream product

• 217972-87-7 benzyl 5-methyl-1,4-diazepane-1-carboxylate 
• 1030377-23-1 benzyl (2-((tert-butoxycarbonyl)amino)ethyl)(3-oxobutanoyl)carbamate 

Relevant articles and documents

PROCESS FOR THE RESOLUTION OF (R,S)-DIAZEPANE AND DIAZEPANONE DERIVATIVES

The present invention relates to a process for the preparation of an acid salt (T) of a compound of formula (A) (A) as well as to the acid salt (T) and the compound (A) as such,wherein R1 is selected from the group consisting of H, PG1 and RA, with RA being or and wherein PG1 is a suitable protecting group, and wherein n is 0 or 1, wherein the acid salt (T) is the salt of one stereoisomer of a chiral acid, preferably wherein the chiral acid salt is a tartaric acid derivative salt, preferably wherein the tartaric acid derivative salt is selected from the group consisting of 2,3-ditoluoyl tartaric acid salt, 2,3-dibenzoyl tartaric acid salt, 2,3-dianisoyl tartaric acid salt, 2,3-dibenzoyl tartaric acid mono(dimethylamide) salt and a mixture of two or more thereof. Further the present invention relates to use of (T) and/or (A) for the preparation of suvorexant.

NOVEL ROUTES OF SYNTHESIS FOR THE PREPARATION OF SUVOREXANT

The present invention relates to a process for the preparation of a compound of formula (A), Further, the present invention relates to the respective compound (A) as such and to its use in the preparation of antifungal agent.

SUBSTITUTED DIAZEPAN OREXIN RECEPTOR ANTAGONISTS

The present invention is directed to substituted diazepan compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.